BEIJING, July 18, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced the filing of its annual report on Form 20-F for the fiscal year ended March 31, 2011 with the U.S. Securities and Exchange Commission (the "SEC"). The annual report, which contains its audited consolidated financial statements for the fiscal year ended March 31, 2011, can be accessed on the Company's investor relations website at http://ir.chinameditech.com as well as on the SEC's website at http://www.sec.gov. Shareholders can receive a hard copy of the Company's annual report free of charge by sending a request to IR@chinameditech.com.
About China Medical Technologies, Inc.China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales personnel and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit http://www.chinameditech.com.ContactsWinnie YamTel: 852-2511-9808Email: IR@chinameditech.com
|SOURCE China Medical Technologies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved